Chris Bond
About Chris Bond
Chris Bond Chief Scientific Officer Biography
Chris Bond serves as the Chief Scientific Officer with extensive experience spanning over 18 years in the biotechnology and pharmaceutical sectors. He has collaborated with a variety of leading companies, including Genentech, OncoMed, Juno Therapeutics, Celgene, and Kite, bringing considerable expertise to his role. His focus has been on pioneering and evolving therapies in the fields of oncology and immunology.
Chris Bond Education and Expertise
Chris Bond holds a Ph.D. in Biochemistry from the University of Washington, establishing a strong foundation for his work in biotechnology and pharmaceuticals. His expertise encompasses protein structure and engineering, immunology, and oncology. Throughout his career, Bond has contributed to numerous patents and has published papers in various scientific journals, showcasing his comprehensive knowledge and ongoing contributions to these fields.
Chris Bond Leading Cell Therapy Development
In his roles at Juno Therapeutics and Kite, Chris Bond led the discovery and preclinical development programs for CAR T and TCR cell therapies targeting both solid and hematological tumors. At Kite, he also spearheaded the development of allogeneic cell therapy platforms, utilizing T cells from donor-derived sources and induced pluripotent stem cells. His work in these areas has been pivotal in advancing cell therapy technologies.
Chris Bond R&D Collaborations in Genome Editing
Chris Bond has led research and development collaborations with prominent genome editing companies, including Editas Medicine and Sangamo Therapeutics. These partnerships have focused on advancing genome editing technologies and integrating them with therapeutic strategies, thus pushing the boundaries of what is achievable in the field of medical biotechnology.
Chris Bond Antibody Discovery and Engineering
During his time at OncoMed Pharmaceuticals, Chris Bond led monoclonal and bi-specific antibody discovery and engineering programs targeting cancer stem cell antigens. His leadership in these programs has been instrumental in developing novel therapeutic options aimed at treating various forms of cancer.